Search Thermo Fisher Scientific
Element Search
Structure Search
Thermo Scientific Chemicals
Tamoxifen, 98%, Thermo Scientific Chemicals
Tamoxifen (citofen, CAS # 10540-29-1) is an antineoplastic agent that has its effect through the estrogen receptors.
Have Questions?
Change view
Catalog number ALFJ63509.03
View Price:Sign InSign in to see your account pricing. Need an account? Register with us today.
Quantity:
1 g
Specifications
Chemical Name or MaterialTamoxifen
CAS10540-29-1
Health Hazard 1H302-H350-H360FD-H362
Health Hazard 2GHS H Statement
H350-H360-H362
May cause cancer.
May damage fertility or the unborn child.
May cause harm to breast-fed children.
H350-H360-H362
May cause cancer.
May damage fertility or the unborn child.
May cause harm to breast-fed children.
Health Hazard 3P201-P202-P260-P263-P264b-P270-P281-P301+P312-P308+P313-P330-P501c
View more
Inhibitor of protein kinase C and induces apoptosis in cancer cells. It is utilized in the study on lipopolysaccharide (LPS)-induced microglial activation to know its effect.
This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.
General Description
- Tamoxifen is a tertiary aminobenzene that acts by competitively binding and antagonizing estrogen receptors to reduce DNA synthesis
- When estradiol cannot bind estrogen receptors, the DNA response element is not activated
- Tamoxifen upregulates the production of TGFb and slows tumor growth
- Tamoxifen inhibits the production of IGF-1, a stimulator of tumor growth
Application
- Tamoxifen may be useful in the study of tumorigenesis, growth, and inflammation
- It is suitable for in vitro experiments
RUO – Research Use Only
General References:
- Mikelman, S.; Guptaroy, B.; Jutkiewicz, E.; Gnegy, M. The Protein Kinase C Inhibitor Tamoxifen Inhibits Neurochemical and Reinforcing Behavioral Effects of Amphetamine. FASEB J. 2015, 29 (1), 930-1011.
- Chlebowski, R. T. IBIS-I tamoxifen update: maturity brings questions. Lancet Oncol. 2015, 16 (1), 7-9.